Brain AVM Case Review & Treatment Pathway Coordination

• Date and circumstances of diagnosis.
• Haemorrhage type and location: intracerebral, intraventricular, subarachnoid or mixed.
• Level of consciousness, neurological deficits and acute interventions.
• Seizure type, frequency, antiseizure medication and control.
• Headache, focal symptoms, cognitive change and functional impact.
• Previous unexplained haemorrhage or neurological events.
• Current modified Rankin Scale or other documented functional baseline where available.

• Initial non-contrast CT and complete DICOM after haemorrhage.
• Brain MRI including susceptibility-sensitive and contrast-enhanced sequences where performed.
• CTA or MRA datasets and reports.
• Serial imaging showing haematoma, oedema, infarction, hydrocephalus or lesion evolution.
• Functional MRI, tractography or other mapping studies where obtained for treatment planning.
• Earlier imaging for comparison.

• Full digital subtraction angiography series from all relevant arterial injections.
• Dynamic runs rather than isolated screenshots.
• Three-dimensional rotational angiography where performed.
• Formal angiography report.
• Nidus dimensions and compartments.
• Feeding arteries, en-passage supply and fistulous components.
• Superficial or deep venous drainage, venous stenosis, ectasia or outflow restriction.
• Associated intranidal, feeding-artery or flow-related aneurysms.

Catheter angiography is invasive and is ordered by the treating team when its diagnostic or planning value justifies the procedural risk.

• Spetzler–Martin grade and the elements used to assign it.
• Eloquent or non-eloquent location.
• Deep venous drainage.
• Compact or diffuse nidus morphology.
• Supplementary surgical grading where used.
• Radiosurgical planning scores or target-volume assessment where relevant.
• Patient age, baseline function, rupture status and major medical risks.

A grade helps communicate treatment complexity but does not independently determine whether an AVM should be treated or which modality should be selected.

• Date, indication and intended role of each embolization.
• Targeted feeder, aneurysm, fistulous component or nidus compartment.
• Embolic agent and delivery technique.
• Procedure report, angiographic images and immediate result.
• Complications, infarction, haemorrhage or neurological change.
• Residual nidus and planned next stage.
• Antiplatelet or anticoagulant management where applicable.

• Operative report and surgical approach.
• Preoperative embolization and intraoperative mapping or monitoring records.
• Intraoperative angiography or fluorescence angiography where performed.
• Early postoperative CT or MRI.
• Postoperative catheter angiography and whether complete resection was confirmed.
• New neurological deficit, seizure, wound or medical complication.
• Rehabilitation and recovery timeline.

• Treatment platform and date.
• Target volume, margin dose and treatment plan.
• Single-session or staged strategy.
• Prior embolization and how it affected target definition.
• Serial MRI showing response, oedema or radiation-related change.
• Follow-up angiography and whether complete obliteration has been confirmed.
• Any haemorrhage or neurological event during the latency period.

• Neurological examination and cognitive assessment.
• EEG and epilepsy review where clinically relevant.
• Antiseizure medication history, adherence and adverse effects.
• Physical, occupational, speech and neuropsychological rehabilitation reports.
• Return-to-school, work, driving and daily-function status.
• Patient-defined recovery and treatment goals.

• Blood pressure and vascular risk history.
• Antiplatelet, anticoagulant and hormonal medication.
• Bleeding disorders, anaesthetic history and contrast allergy.
• Kidney function relevant to contrast procedures.
• Pregnancy, planned pregnancy or fertility-treatment questions.
• Upcoming surgery, long-distance travel or activities requiring individualized medical advice.

• Access to local stroke, neurosurgical and neurointerventional emergency care.
• Ability to complete serial MRI, angiography and neurological follow-up.
• Family or caregiver support.
• Travel fitness after haemorrhage or treatment.
• Rehabilitation and seizure follow-up availability.
• Insurance, funding or authorization requirements for staged treatment.

A brain AVM has a parenchymal nidus connecting arteries and veins. An intracranial aneurysm is a focal arterial outpouching. A dural arteriovenous fistula is a shunt within the dura and is classified largely by venous drainage. A cavernous malformation has different imaging behaviour and usually does not appear as a high-flow shunt on catheter angiography. These diagnoses require different risk models and treatment pathways.

After rupture, immediate priorities include stabilization, management of intracerebral or intraventricular haemorrhage, hydrocephalus, mass effect and identification of a treatable weak point. Definitive AVM treatment may be immediate, delayed or staged depending on the haemorrhage pattern, neurological condition and angioarchitecture.

For an unruptured AVM, intervention is not automatic. The expected lifetime haemorrhage risk must be weighed against the short- and long-term risks of each treatment strategy and the possibility that observation may be safer.

The randomized ARUBA trial found more early stroke or death in the combined intervention group than with medical management alone during the available follow-up. The trial remains highly relevant to informed consent, particularly because preventive treatment can cause immediate harm in a lesion that may never rupture.

ARUBA did not establish that every unruptured AVM should remain untreated. Limitations include modest sample size, heterogeneous interventions, relatively short follow-up for a lifelong condition and limited power to define carefully selected subgroups. Subsequent specialist-centre cohorts have reported different outcomes in selected low-grade or radiosurgical cases, but these are not equivalent to randomized evidence. The public-facing conclusion should be individualized multidisciplinary review—not a universal treatment or non-treatment rule.

Haemorrhage risk varies with prior rupture, associated aneurysms, deep location or drainage and other lesion-specific features, while published estimates differ across cohorts. A population average should not be presented as a precise prediction for one patient. Risk counselling should also account for age, life expectancy, functional status and uncertainty.

DSA often provides the most detailed dynamic evaluation of nidus compartments, arterial supply, venous drainage, fistulous points and associated aneurysms and is commonly used for treatment planning and confirmation of obliteration. It is an invasive procedure with stroke, access-site, contrast and other risks. The treating team decides when its additional information is necessary.

The Spetzler–Martin system combines nidus size, eloquence and deep venous drainage to estimate microsurgical risk. Supplementary grading may add age, rupture status and nidus compactness. These systems support communication and surgical assessment; they do not estimate every treatment modality equally and do not decide whether intervention is justified.

Microsurgery may be discussed for selected AVMs where complete resection can be achieved at an acceptable neurological risk, often in smaller, surgically accessible lesions. Its potential advantage is immediate elimination of the treated shunt when complete resection is angiographically confirmed. Risks include haemorrhage, infarction, neurological deficit, seizure, infection and medical or anaesthetic complications.

“Complete resection” should be confirmed with appropriate vascular imaging. A visually satisfactory operation or postoperative MRI alone may not exclude a small residual shunt.

Radiosurgery may be considered for selected smaller or deeper AVMs, including lesions where open surgery carries greater risk. Obliteration develops gradually rather than immediately, and haemorrhage risk persists during the latency period. Incomplete obliteration, radiation-related oedema, neurological symptoms, cyst formation or tissue injury can occur.

Serial MRI monitors response and adverse effects, while catheter angiography may be required to confirm complete obliteration. A reduced nidus on MRI should not automatically be labelled cured.

Embolization can serve different purposes: control of a ruptured aneurysm or focal weak point, reduction of selected surgical or radiosurgical complexity, staged treatment of particular compartments, or—in carefully selected anatomy—attempted definitive occlusion. These indications are not interchangeable.

Partial embolization does not necessarily remove future haemorrhage risk and can change haemodynamics or complicate later target definition. Risks include haemorrhage, ischaemic stroke, catheter or vessel injury, unintended embolization and access-site complications. Public copy should not describe embolization as a routine cure for brain AVM.

Intranidal, feeding-artery and flow-related aneurysms may influence rupture-source assessment and treatment sequencing. The aneurysm may be managed separately, treated as part of the AVM strategy or observed depending on morphology, location and clinical context. Aneurysm devices such as coils, stents and flow diverters should not be listed as general AVM treatments without explaining the specific target.

A pathway may combine embolization with microsurgery or radiosurgery, or use staged radiosurgical or endovascular treatment. Combining modalities is not automatically safer or more advanced; each step adds its own risk, imaging requirement and interval of residual haemorrhage exposure. The sequence should have a defined purpose and completion plan.

Observation is an active plan rather than absence of care. It may include seizure treatment, management of headache and vascular risk factors, counselling about new neurological symptoms, individualized discussion of antithrombotic medication and pregnancy, and a defined imaging and clinical follow-up strategy. Surveillance cannot guarantee that rupture will not occur.

Seizures can be the presenting feature of an unruptured AVM or follow haemorrhage or treatment. Antiseizure management is individualized. AVM obliteration does not guarantee seizure freedom, and treatment undertaken mainly for seizure control requires realistic counselling. Driving, work and medication decisions remain within the treating neurology pathway.

Pregnancy and planned pregnancy require individualized counselling based on rupture history, symptoms, lesion anatomy and maternal health. Website copy should not give universal advice about pregnancy, mode of delivery or preventive treatment. Antiplatelet or anticoagulant medication may be necessary for other conditions; decisions should weigh competing risks with the relevant treating specialists rather than stopping medication without guidance.

Residual shunting after surgery, embolization or radiosurgery requires review of the treatment objective, timing and confirmatory imaging. A residual AVM may be retreated, observed or incorporated into a staged plan. Rare recurrence can occur after previously documented obliteration, particularly in younger patients, so follow-up strategies may differ by age and treatment history.

Meaningful outcomes include survival, stroke, neurological function, cognition, seizure control, rehabilitation, quality of life and complete angiographic obliteration where treatment aims at cure. Technical success, percentage nidus reduction or completion of a procedure is not equivalent to a favourable patient outcome. No treatment should be described as guaranteeing permanent protection from haemorrhage.